SecBot SecBot
SECBOTREPLAY Home › Report › ABBV

ABBV · AbbVie reported Q1 2026 adjusted EPS of $2.65, above the prior company…

AbbVie Inc. · 8-K filed Apr 29, 2026 at 07:50 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 29, 2026 at 07:50 ET

AbbVie reported Q1 2026 adjusted EPS of $2.65, above the prior company guidance range of $2.56-$2.60, and revenue of $15.002B (+12.4% YoY). The company raised full-year 2026 adjusted EPS guidance from $13.96-$14.16 to $14.08-$14.28, driven by strong growth in immunology (Skyrizi +30.9%, Rinvoq +23.3%) and neuroscience (+26.0%).

  • Q1 2026 net revenue $15.002B, +12.4% YoY reported, +10.3% operational
  • Q1 2026 adjusted diluted EPS $2.65, +7.7% YoY; GAAP EPS $0.39, -45.8% YoY
  • Full-year 2026 adjusted diluted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16
  • Immunology revenue $7.290B (+16.4%), neuroscience $2.875B (+26.0%)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access